---
title: "Positive Report for CAMP4 Therapeutics Corporation (CAMP) from J.P. Morgan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290565368.md"
description: "J.P. Morgan analyst Anupam Rama upgraded CAMP4 Therapeutics (CAMP) to a Buy with a $9.00 price target, noting the stock closed at $4.20. Rama, a 5-star analyst, covers the healthcare sector. The stock holds a Strong Buy consensus with an average price target of $8.36. Additionally, Chardan Capital initiated coverage with a Buy rating and a $6.50 target in June."
datetime: "2026-06-23T12:37:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290565368.md)
  - [en](https://longbridge.com/en/news/290565368.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290565368.md)
---

# Positive Report for CAMP4 Therapeutics Corporation (CAMP) from J.P. Morgan

J.P. Morgan analyst Anupam Rama upgraded CAMP4 Therapeutics Corporation to a Buy yesterday and set a price target of $9.00. The company’s shares closed yesterday at $4.20.

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Rama is a 5-star analyst with an average return of 21.0% and a 50.92% success rate. Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Travere Therapeutics, and Olema Pharmaceuticals.

CAMP4 Therapeutics Corporation has an analyst consensus of Strong Buy, with a price target consensus of $8.36, implying a 99.05% upside from current levels. In a report released on June 10, Chardan Capital also initiated coverage with a Buy rating on the stock with a $6.50 price target.

### Related Stocks

- [CAMP.US](https://longbridge.com/en/quote/CAMP.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md)
- [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md)
- [OLMA.US](https://longbridge.com/en/quote/OLMA.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [Camp4 Therapeutics CEO Josh Mandel-Brehm acquires 6,551 common shares for $10,809.15](https://longbridge.com/en/news/295017282.md)
- [Yuri Maricich Acquires 6,551 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock](https://longbridge.com/en/news/295030105.md)
- [Definium Therapeutics (DFTX) Receives a Buy from Wells Fargo](https://longbridge.com/en/news/295787298.md)
- [Wedbush Reaffirms Their Hold Rating on Apogee Therapeutics (APGE)](https://longbridge.com/en/news/295552883.md)
- [Canaccord Genuity Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)](https://longbridge.com/en/news/295789301.md)